Bionomic

Bionomics is a clinical-stage biopharmaceutical company focused on developing novel, small molecule ion channel modulators for the treatment of central nervous system (CNS) disorders. The company's lead candidate, BNC210, is a negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor currently being evaluated in Phase 2 clinical trials for Post-Traumatic Stress Disorder (PTSD) and Social Anxiety Disorder (SAD). Bionomics leverages its proprietary IonX and MultiCore platforms to identify and optimize drug candidates targeting ion channels, which play a critical role in neurotransmission. Headquartered in Australia with a presence in the United States, the company aims to address significant unmet needs in mental health and cognitive conditions.